Robert J Gould's Net Worth
$19.7 Million
Who is Robert J Gould?
Robert J Gould has an estimated net worth of $19.7 Million. This is based on reported shares across multiple companies, which include Fulcrum Therapeutics, Inc., Epizyme, Inc., and Turnstone Biologics Corp..
SEC CIK
Robert J Gould's CIK is 0001577034
Past Insider Trading and Trends
2014 was Robert J Gould's most active year for acquiring shares with 14 total transactions. Robert J Gould's most active month to acquire stocks was the month of May. 2014 was Robert J Gould's most active year for disposing of shares, totalling 31 transactions. Robert J Gould's most active month to dispose stocks was the month of May. 2022 saw Robert J Gould paying a total of $1,865,441.76 for 256,939 shares, this is the most they've acquired in one year. In 2014 Robert J Gould cashed out on 630,000 shares for a total of $8,683,890.21, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Fulcrum Therapeutics, Inc. (FULC) Snapshot price: $8.54
Interim President & CEORobert J Gould owns 499,864 units of Common Stock which is worth $4,268,838.56. From 2019 to 2024 Robert J Gould acquired a total of 237,939 shares in Fulcrum Therapeutics, Inc. at a cost of $1,865,441.76, Robert also disposed a total of 295,420 shares of Fulcrum Therapeutics, Inc. equalling to $4,436,664.21.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 27
| |||
Form 4
| -1.34% | -6.77K |
$15.00 | -$101,490.00 | 499.86K |
Scheduled
|
Jan 13
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 27
| |||
Form 4
|
—
|
0
|
$7.97 | -$17,844.46 | 506.63K |
Scheduled
|
Jun 7
| ||
Form 4
|
—
|
0
|
$7.92 | -$10,493.46 | 506.63K |
Scheduled
|
Jun 2 - Jun 6
| ||
Form 4
|
—
|
0
|
$15.93 | -$91,081.42 | 506.63K |
Scheduled
|
Apr 7
| ||
Form 4
|
—
|
0
|
$16.00 | -$1,537,755.87 | 506.63K |
Scheduled
|
Apr 1 - Apr 5
| ||
Form 4
| -1.94% | -10.00K |
$12.16 | -$121,578.33 | 506.63K |
Scheduled
|
Mar 15 - Mar 16
| ||
Form 4
| -1.57% | -8.21K |
$14.27 | -$117,197.40 | 516.63K |
Scheduled
|
Feb 16
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
| -1.87% | -10.00K |
$12.08 | -$120,826.00 | 524.85K |
Scheduled
|
Jan 20
| ||
Form 4
| -0.47% | -2.50K |
$20.00 | -$50,000.00 | 534.85K |
Scheduled
|
Jul 8
| ||
Form 4
| -0.46% | -2.50K |
$20.80 | -$51,992.00 | 537.35K |
Scheduled
|
Jun 25
| ||
Form 4
| -0.03% | -156.00 |
$20.00 | -$3,120.00 | 539.85K |
Scheduled
|
Jun 9
| ||
Form 4
| -0.63% | -3.43K |
$20.17 | -$69,251.16 | 540K |
Scheduled
|
Jun 5
| ||
Form 4
| -0.51% | -2.80K |
$20.09 | -$56,250.43 | 543.43K |
Scheduled
|
Jun 3 - Jun 4
| ||
Form 4
| -0.51% | -2.80K |
$20.00 | -$56,040.00 | 546.23K |
Scheduled
|
Jun 1 - Jun 2
| ||
Form 4
| -0.60% | -3.31K |
$20.04 | -$66,301.91 | 549.04K |
Scheduled
|
May 28 - May 29
| ||
Form 4
| -0.45% | -2.50K |
$20.00 | -$50,000.00 | 552.35K |
Scheduled
|
May 26
| ||
Form 4
| -0.45% | -2.50K |
$20.00 | -$50,000.00 | 554.85K |
Scheduled
|
Feb 19
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Epizyme, Inc. No price found
President & CEORobert J Gould used to own units in Common Stock, par value $0.0001 per share but no longer holds any shares there. In the year 2013 Robert J Gould acquired a total of 542,108 shares in Epizyme, Inc. at a cost of $271,299.15, Robert also disposed a total of 542,108 shares of Epizyme, Inc. equalling to $13,165,398.16.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$9.26 | -$561,956.49 |
0
|
Scheduled
|
Dec 29 - Dec 30
| ||
Form 4
|
—
|
0
|
$10.19 | -$1,161,142.28 |
0
|
Scheduled
|
Sep 8
| ||
Form 4
|
—
|
0
|
$11.24 | -$1,287,754.02 |
0
|
Scheduled
|
Aug 3
| ||
Form 4
|
—
|
0
|
$11.87 | -$1,362,480.08 |
0
|
Scheduled
|
Jul 6
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 4
|
—
|
0
|
$12.73 | -$733,323.37 |
0
|
Scheduled
|
Nov 3
| ||
Form 4
|
—
|
0
|
$13.40 | -$773,000.30 |
0
|
Scheduled
|
Oct 1
| ||
Form 4
|
—
|
0
|
$16.99 | -$988,600.58 |
0
|
Scheduled
|
Sep 2
| ||
Form 4
|
—
|
0
|
$15.38 | -$891,956.24 |
0
|
Scheduled
|
Aug 1
| ||
Form 4
|
—
|
0
|
$16.02 | -$930,495.36 |
0
|
Scheduled
|
Jul 1
| ||
Form 4
|
—
|
0
|
$11.36 | -$650,760.24 |
0
|
Scheduled
|
Jun 2
| ||
Form 4
|
—
|
0
|
$11.21 | -$642,137.77 |
0
|
Scheduled
|
May 1
| ||
Form 4
|
—
|
0
|
$10.37 | -$591,438.00 |
0
|
Scheduled
|
Apr 7
| ||
Form 4
|
—
|
0
|
$14.88 | -$1,724,400.00 |
0
|
Feb 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 28
| |||
Form 4
|
—
|
0
|
$10.25 | -$594,654.27 |
0
|
Scheduled
|
Jan 2
| ||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Turnstone Biologics Corp. (TSBX) Snapshot price: $0.5884
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||